Tara Lin, MD
Hematology & Oncology · Kansas City, KSNPI 1013172253
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,200 of the $27,285 with a category attached, or 66.7%. 8 manufacturers reported payments, led by Syndax Pharmaceuticals, Inc. at 36.2% of the total. 2025 is the largest year on record at $12,689, 2.3 times the $5,418 reported in 2019.
Across 42 payments — averaging $649.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Syndax Pharmaceuticals, Inc.$10K
- Daiichi Sankyo Inc.$6K
- Jazz Pharmaceuticals Inc.$4K
- Pfizer$4K
- Janssen Scientific Affairs, LLC$3K
- Boston Scientific$205
- plus $164 from 2 others
Across 282 payments — averaging $7614.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$1.3M
- Syndax Pharmaceuticals, Inc.$206K
- Genentech, Inc.$183K
- Aptevo Therapeutics Inc$156K
- Incyte Corporation$131K
- Astellas Pharma Global Development$110K
- plus $93K from 8 others
What the payments were for
- Consulting fees$18,20067%
- Speaking & faculty fees$4,02315%
- Travel & lodging$3,31912%
- Food & beverage$1,7216%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 13 | $9,883 |
| Daiichi Sankyo Inc. | 9 | $5,994 |
| Jazz Pharmaceuticals Inc. | 8 | $4,232 |
| Pfizer | 4 | $4,001 |
| Janssen Scientific Affairs, LLC | 4 | $2,806 |
| Boston Scientific | 2 | $205 |
| Bristol Myers Squibb | 1 | $120 |
| Servier Pharmaceuticals LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,285 in reported general payments places this provider in the 75th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 21 | $30,020 |
| Levofloxacin | 11 | $193 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Kansas City
- Jeffrey WeitzelKansas City$117K
- Joseph McGuirkKansas City$113K
- Christopher SirridgeKansas City$43K
- Jeries KortKansas City$2K
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Marc HoffmannOverland Park$153K
- Priyanka SharmaWestwood$135K
- Gary DoolittleWestwood$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.